A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease

Figure 6 ANG3070 decreases phosphorylated platelet-derived growth factor receptor in the PCK rat kidney. A: Western blot analysis of kidney homogenates showed intense phosphorylated platelet-derived growth factor receptor (pPDGFR) levels in the PCK + vehicle (Veh) cohort compared to the WT and PCK + ANG3070 cohorts. A similar expression profile was seen with the fibrotic marker α smooth muscle actin (αSMA) in these kidneys. GAPDH expression is shown at the bottom; B: pPDGFR in renal homogenates from 10 wk old WT, PCK + Veh and PCK + ANG3070-treated animals was visualized with anti-PDGFR-α antibody and submitted to densitometric analysis with normalization to GAPDH. ANG3070 treatment was associated with a marked reduction in phosphorylated PDGFR levels (^bP < 0.01, vs WT; ^dP <0.01, vs PCK + Veh).